Drug intelligence / Profile preview

Livalgel-M

Development stage: Unknown
Lead developer: Livonian Biotech Millennium
Administration: Topical

Overview

Livalgel-M is a topical joint-skin gel developed by Livonian Biotech Millennium (LBM SIA) in partnership with the Institute of Innovative Biomedical Technologies (IBTI). It is formulated with mannuronic and guluronic acids extracted from brown algae. The product is marketed for the relief of joint discomfort and is patented in Europe. While the specific molecular mechanism of action for joint relief is not fully described in available literature, the gel utilizes the properties of these algal-derived uronic acids for topical application.

Brand names: Livalgel-M

Beyond the preview

Go deeper on Livalgel-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Livalgel-M.

Explore the full profile